Global Health FY26 Net Profit Rises 15.1%; Record Q4 Revenue
Global Health reported record Q4 FY26 revenue of INR 11,958 million, a 25.3% YoY increase, and FY26 net profit of INR 5,541 million, up 15.1%. The company added 623 beds during the year, including a new facility in Ranchi, and announced expansion projects in Guwahati and Varanasi. The Board recommended a final dividend of INR 0.50 per share.

*this image is generated using AI for illustrative purposes only.
Global Health Limited has announced its audited consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors, at its meeting held on May 14, 2026, approved the results. The company delivered its highest ever quarterly revenue of INR 11,958 million in Q4 FY26, representing a growth of 25.3% year-on-year. For the full year, consolidated total income stood at INR 45,089 million, up by 19.6% compared to the prior year. Profit after tax for FY26 increased by 15.1% to INR 5,541 million. The audio recording of the earnings conference call held on May 15, 2026, hosted by ICICI Securities, has been made available on the company's investor relations page.
Consolidated Financial Highlights
The following table summarizes the key consolidated financial metrics for the quarter and full year:
| INR million | FY2026 | FY2025 | Y-o-Y Growth % | Q4 FY26 | Q3 FY26 | Q4 FY25 | Y-o-Y Growth % |
|---|---|---|---|---|---|---|---|
| Revenue from operations | 44,103 | 36,923 | 19.4% | 11,590 | 11,211 | 9,313 | 24.5% |
| Other income | 986 | 789 | 24.9% | 367 | 217 | 229 | 60.3% |
| Total income | 45,089 | 37,713 | 19.6% | 11,958 | 11,428 | 9,542 | 25.3% |
| EBITDA | 10,560 | 9,562 | 10.4% | 2,906 | 2,494 | 2,476 | 17.4% |
| Profit after tax | 5,541 | 4,813 | 15.1% | 1,417 | 950 | 1,014 | 39.7% |
Consolidated EBITDA for the year stood at INR 10,560 million, with margins at 23.4%. Excluding the recently operationalized Noida hospital, EBITDA was INR 11,343 million, up 18.6% year-on-year with margins of 25.7%. The Noida facility, inaugurated in November 2025, reported revenue of INR 906 million and an EBITDA loss of INR 783 million for the year. Total bed capacity grew by 20.5% with the addition of 623 beds during the year, including new facilities in Ranchi and capacity expansion in Patna.
Q4 Operational Performance
For the quarter ended March 31, 2026, Global Health reported consolidated EBITDA of INR 2,906 million, a growth of 17.4% year-on-year, with margins at 24.3%. EBITDA excluding Noida grew 27.0% to INR 3,142 million with improved margins of 27.5%. Profit after tax for the quarter was INR 1,417 million, a robust increase of 39.7% year-on-year. Operational metrics showed strong volume growth, with in-patient count increasing by 23.0% and out-patient count rising by 27.5% during the quarter. Occupancy stood at approximately 61% on expanded bed capacity.
Strategic Developments
During the year, the company operationalized a 110-bed hospital in Ranchi and expanded capacity in Patna. The Board approved a new 400-bed hospital project in Guwahati and a 400-bed facility in Varanasi under a build-to-suit lease arrangement. Additionally, the company executed a Business Transfer Agreement with Asian Institute of Oncology Private Limited for an 80-bed Advanced Super Speciality Hospital in Indore, expected to be operational in Q2 FY27. The company also onboarded over 550 doctors, including 200+ senior clinicians, to strengthen clinical capabilities.
Management Commentary
Management highlighted that the Noida hospital is ramping up steadily, with Q4 EBITDA loss reducing to INR 236 million from INR 320 million in Q3. The facility achieved NABH accreditation within six months of operations. The company remains focused on expanding its footprint through greenfield projects and selective inorganic expansion, with total project capex estimated at approximately INR 45,000 million over the next five years. The company exited FY26 with a net cash position of INR 5,906 million.
Dividend Declaration
The Board of Directors has recommended a final dividend of 25% on the face value of INR 2 per share, amounting to INR 0.50 per equity share for the financial year ended March 31, 2026. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.
Historical Stock Returns for Global Health
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.67% | +2.67% | +5.85% | +3.26% | +3.60% | +198.58% |
Given the Noida hospital's EBITDA loss narrowing from INR 320 million in Q3 to INR 236 million in Q4, what is the projected timeline for the facility to reach EBITDA breakeven, and how will this impact consolidated margins in FY27?
With INR 45,000 million in capex planned over the next five years for greenfield projects in Guwahati, Varanasi, and beyond, how does Global Health intend to fund this expansion while maintaining its current net cash position?
How might the integration of the Asian Institute of Oncology's Indore facility in Q2 FY27 contribute to Global Health's oncology revenue mix, and could this signal a broader inorganic acquisition strategy in super-speciality segments?


































